Gayatri BioOrga.

Which are the latest news on Gayatri BioOrga.?

Why is Gayatri BioOrganics Ltd falling/rising?

As of 16-Jun, Gayatri BioOrganics Ltd's stock price is at 7.95, reflecting a 0.5% decline and a significant drop of 46.36% over the past month. The stock is underperforming compared to the benchmark Sensex and shows bearish trends with decreased investor participation.

As of 16-Jun, Gayatri BioOrganics Ltd's stock price is falling, currently at 7.95, which reflects a decrease of 0.04 or 0.5%. This decline is part of a broader trend, as the stock has experienced a significant drop of 46.36% over the past month and 54.93% year-to-date. In contrast, the benchmark Sensex has shown a positive return of 2.09% over the same month and a decline of only 9.87% year-to-date, indicating that Gayatri BioOrganics Ltd is underperforming relative to the market.<BR><BR>Today's performance is noted to be inline with the sector, but it follows a trend reversal after two consecutive days of gains, suggesting that the recent uptick was not sustained. Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend.<BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by 78.99% compared to the 5-day average, indicating a lack of interest or confidence among investors. This combination of poor performance metrics, declining investor engagement, and unfavorable comparisons to the benchmark suggests that the stock's price is falling due to a lack of positive momentum and investor confidence.

How big is Gayatri BioOrga.?

As of 10th June, Gayatri BioOrganics Ltd has a market capitalization of 62.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit loss of 1.11 Cr in the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds at a loss of 35.89 Cr and Total Assets valued at 1.66 Cr.

As of 10th June, Gayatri BioOrganics Ltd has a market capitalization of 62.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit loss of 1.11 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds at a loss of 35.89 Cr and Total Assets valued at 1.66 Cr.

Who are in the management team of Gayatri BioOrga.?

The management team of Gayatri BioOrga includes T V Sandeep Kumar Reddy (Executive Chairman), Murali Vittala, P V Narayana Rao, Ch Ramachandra Seshaprasad (all Independent Directors), K. Sridhar Reddy (Whole-time Director), Meenakshi Ramchand Sachdeva (Director), and Aamir Tak (Company Secretary & Compliance Officer).

The management team of Gayatri BioOrga includes the following individuals:<BR><BR>1. T V Sandeep Kumar Reddy - Executive Chairman<BR>2. Murali Vittala - Independent Director<BR>3. P V Narayana Rao - Independent Director<BR>4. Ch Ramachandra Seshaprasad - Independent Director<BR>5. K. Sridhar Reddy - Whole-time Director<BR>6. Meenakshi Ramchand Sachdeva - Director<BR>7. Aamir Tak - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Gayatri BioOrga.?

Peers of Gayatri BioOrga. include ARCL Organics, AG Ventures, Archit Organosys, Polychem, Sh. Hari Chem., Ritesh Intl., Shreyas Interm., Camex, and TCM. Ritesh Intl. has the highest 1-year return at 24.60%, while Gayatri BioOrga. has a 1-year return of 6.02%.

Peers: The peers of Gayatri BioOrga. are ARCL Organics, AG Ventures, Archit Organosys, Polychem, Sh. Hari Chem., Ritesh Intl., Shreyas Interm., Camex, and TCM.<BR><BR>Quality Snapshot: Excellent management risk is observed at ARCL Organics, while Average management risk is found at Polychem, Sh. Hari Chem., and Ritesh Intl., and the rest have Below Average management risk. Growth is rated as Good at Sh. Hari Chem., while Average growth is noted at Polychem, Ritesh Intl., and Archit Organosys, and the rest have Below Average growth. Capital Structure is Excellent at AG Ventures, Good at ARCL Organics and Polychem, Average at Archit Organosys and Camex, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: Ritesh Intl. has the highest 1-year return at 24.60%, while AG Ventures has the lowest at -59.81%. Gayatri BioOrga.'s own 1-year return is 6.02%, which is higher than AG Ventures but lower than Ritesh Intl. Additionally, the six-month returns are negative for ARCL Organics, AG Ventures, Polychem, Sh. Hari Chem., Shreyas Interm., TCM, and Gayatri BioOrga.

What does Gayatri BioOrga. do?

Gayatri BioOrganics Ltd is a micro-cap company in the commodity chemicals industry, previously known as Starchem Industries, with no net profit reported for March 2026 and a market cap of INR 62 Cr. The company has a negative debt-equity ratio and a low return on equity of 2.73%.

Overview:<BR>Gayatri BioOrganics Ltd operates in the commodity chemicals industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Starchem Industries Limited' in 1991. It underwent several name changes, becoming Gayatri Starchem Limited in 1997 and finally Gayatri BioOrganics Limited in 2008. The latest quarterly results reported are for March 2026, showing no net profit.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 62 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 42<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -1.02<BR>Return on Equity: 2.73%<BR>Price to Book: -1.75<BR><BR>Contact Details:<BR>Address: 6-3-1090 B-Block 3rd Floor, TSRTowers, Rajbhavan Rd, Somajiguda, Hyderabad, Telangana: 500082<BR>Tel: 91-40-66100111<BR>Email: info@gayatribioorganics.com<BR>Website: http://www.gayatribioorganics.com

Should I buy, sell or hold Gayatri BioOrganics Ltd?

Are Gayatri BioOrganics Ltd latest results good or bad?

Gayatri BioOrganics Ltd's latest results are concerning, showing a net loss of ₹0.42 crores for Q4 FY26 and an operating loss of ₹0.32 crores, with no revenue generated for seven consecutive quarters. The company's financial outlook is bleak, marked by negative book value per share and significant shareholder equity erosion.

The latest results for Gayatri BioOrganics Ltd are quite concerning. The company reported a net loss of ₹0.42 crores for Q4 FY26, which marks a staggering 147.06% decline compared to the same quarter last year. This is compounded by an operating loss of ₹0.32 crores, the worst performance in the last seven quarters. <BR><BR>Additionally, the company has not generated any revenue for seven consecutive quarters, indicating a complete operational shutdown. The book value per share is negative at ₹-4.56, reflecting a total erosion of shareholder equity, which stands at ₹-35.89 crores. <BR><BR>While the stock has shown a one-year return of +91.83%, this performance appears to be driven by speculative trading rather than any fundamental improvement in the company's operations. The lack of institutional support and the ongoing financial distress suggest that the outlook for Gayatri BioOrganics is bleak. Overall, the results can be classified as bad, highlighting a company in severe financial decline with no clear path to recovery.

When is the next results date for Gayatri BioOrganics Ltd?

The next results date for Gayatri BioOrganics Ltd is 19 May 2026.

The next results date for Gayatri BioOrganics Ltd is scheduled for 19 May 2026.

How has been the historical performance of Gayatri BioOrga.?

Gayatri BioOrga has faced significant financial challenges, reporting minimal revenue and consistent losses, with net sales dropping to zero in 2024 and 2025, and negative reserves of -114.68 Cr by March 2025. The company has not generated any cash flow from operations since March 2020.

Answer:<BR>The historical performance of Gayatri BioOrga shows a challenging trend with minimal revenue generation and consistent losses over the years.<BR><BR>Breakdown:<BR>Gayatri BioOrga reported net sales of 1.67 Cr in March 2023, but this figure dropped to 0.00 Cr in both March 2024 and March 2025, indicating a complete halt in revenue generation. The total operating income mirrored this trend, remaining at 0.00 Cr for the last two years after a peak in March 2023. The company's expenditures, excluding depreciation, were 2.44 Cr in March 2023, decreasing to 0.45 Cr by March 2025, yet the operating profit continued to be negative, with losses of -0.45 Cr in March 2025 compared to -0.77 Cr in March 2023. The profit before tax also remained negative, with a loss of -0.73 Cr in March 2025. The company's reserves have been in a negative state, reaching -114.68 Cr in March 2025, while shareholder's funds also reflected a negative balance of -35.89 Cr. Cash flow from operating activities has been non-existent since March 2020, with no cash inflow or outflow reported in the last three years. Overall, Gayatri BioOrga's financial performance indicates significant operational challenges and a lack of profitability.

Is Gayatri BioOrga. overvalued or undervalued?

As of April 25, 2023, Gayatri BioOrga is classified as risky and overvalued, with negative key ratios indicating financial struggles, despite a 34.16% return over the past year, outperforming the Sensex's 7.57%.

As of 25 April 2023, the valuation grade for Gayatri BioOrga. has moved from does not qualify to risky. The company is currently assessed as overvalued. Key ratios include a PE ratio of -58.43, an EV to EBIT of -95.74, and a ROCE of -38.46%. <BR><BR>In comparison to peers, Solar Industries is classified as very expensive with a PE ratio of 123.77, while Godrej Industries is attractive with a PE ratio of 46.63. The significant negative ratios for Gayatri BioOrga. suggest that the company is struggling financially, which is reflected in its poor performance relative to the Sensex, although it has outperformed the index over the past year with a return of 34.16% compared to the Sensex's 7.57%.

What is the technical trend for Gayatri BioOrga.?

As of May 14, 2025, Gayatri BioOrga's technical trend is bullish, supported by strong daily and weekly indicators, despite mild bullishness in the monthly MACD and KST.

As of 14 May 2025, the technical trend for Gayatri BioOrga has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate a bullish stance. The weekly KST is bullish, further reinforcing the upward momentum. Although the monthly MACD and KST are only mildly bullish, the overall strength of the trend is supported by the daily indicators. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting a potential for continued upward movement. The Dow Theory shows a mildly bullish trend on the weekly chart, but no trend on the monthly. Overall, the current technical stance is bullish with strong indicators from the daily and weekly time frames.

Who are the top shareholders of the Gayatri BioOrga.?

The top shareholders of Gayatri BioOrga include promoter Sandeep Kumar Reddy Tikkavarapu with 21.59% and public shareholder Fursa Mauritius Spv 1 with 23.48%. Individual investors hold 53.01% of shares, while mutual funds and foreign institutional investors hold minor stakes.

The top shareholders of Gayatri BioOrga include Sandeep Kumar Reddy Tikkavarapu, who is the promoter with the highest holding at 21.59%. Additionally, the highest public shareholder is Fursa Mauritius Spv 1, holding 23.48%. Individual investors collectively hold 53.01% of the shares. The company also has some mutual fund representation, with three schemes holding 0.65%, and one foreign institutional investor holding 0.01%. There are no pledged promoter holdings reported.

Has Gayatri BioOrga. declared dividend?

No Dividend History Available